Panacea Biotec (BOM:531349) Cyclically Adjusted PB Ratio: (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
63 GF Score
Price ₹388.35
GF Value ₹404.52
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Panacea Biotec Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Panacea Biotec  (BOM:531349) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Panacea Biotec Cyclically Adjusted PB Ratio Related Terms


Panacea Biotec Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec Cyclically Adjusted PB Ratio Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.25 2.57

Panacea Biotec Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.24 0.00 2.57 0.00

BOM:531349 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Panacea Biotec's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Biotec Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacea Biotec's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Panacea Biotec's Cyclically Adjusted PB Ratio falls into.


BOM:531349
63GF Score
Panacea Biotec Ltd BOM:531349
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panacea Biotec Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Panacea Biotec's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Panacea Biotec's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Panacea Biotec Quarterly Data

Book Value per Share CPI Adj_Book
201203 142.874 76.889 310.982
201303 102.152 85.687 199.515
201403 83.708 91.425 153.231
201503 76.944 97.163 132.531
201603 65.887 102.518 107.558
201703 58.068 105.196 92.381
201803 50.395 109.786 76.822
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 57.207 118.202 80.997
201906 0.000 120.880 0.000
201909 46.874 123.175 63.687
201912 0.000 126.235 0.000
202003 32.454 124.705 43.554
202006 0.000 127.000 0.000
202009 -22.099 130.118 -28.424
202012 0.000 130.889 0.000
202103 -37.337 131.771 -47.420
202106 0.000 134.084 0.000
202109 -55.320 135.847 -68.152
202112 0.000 138.161 0.000
202203 143.122 138.822 172.541
202206 0.000 142.347 0.000
202209 131.936 144.661 152.636
202212 0.000 145.763 0.000
202303 137.729 146.865 156.947
202306 0.000 150.280 0.000
202309 138.282 151.492 152.764
202312 0.000 152.924 0.000
202403 137.475 153.035 150.342
202406 0.000 155.789 0.000
202409 135.983 157.882 144.144
202412 0.000 158.323 0.000
202503 136.289 157.552 144.771
202506 0.000 159.755 0.000
202509 134.922 162.289 139.135
202512 0.000 163.281 0.000
202603 136.298 164.272 138.858
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be undervalued. The current stock price of ₹388.35 is trading 4% below its estimated GF Value™ of ₹404.52. GuruFocus considers Panacea Biotec to be Fairly Valued.

Key valuation signals for BOM:531349:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹404.52 vs. price of ₹388.35 (4% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
63GF Score

Get the complete analysis for BOM:531349

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹388.35
Price
₹404.52
GF Value